Related Experiment Video
Updated: May 19, 2026
Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats
N A Salem1, N Assaf, H H Ahmed
1Department of Narcotics, Ergogenic Aids and Poisons, National Research Centre, Cairo, Egypt. dr_nsalem@yahoo.com
Background:
Obesity, a worldwide health problem, is a metabolic disease currently associated with a cluster and progressive pathologies presenting several features of metabolic syndrome.
Objectives:
The present study was undertaken to investigate the effect of rimonabant, simvastatin and their combination on obesity associated metabolic disorder mediators in adult male rats.
Materials And Methods:
Fifty adult male Wistar rats weighing (120 +/- 10 g) were divided into five groups: Group 1 was kept on standard rodent chow and served as normal diet control. Group 2 was given high fat diet (HFD) for twenty weeks and served as HFD control. Groups 3, 4 and 5 administered HFD for ten weeks and then orally received rimonabant (2 mg/kg/day), simvastatin (10 mg/kg/day), combination of both drugs, respectively for another ten weeks with continuing feeding HFD.
Results:
The current results showed that the treatment of HFD rats with either rimonabant or simvastatin significantly reduced body mass index, total cholesterol, triacylglycerides, low density lipoproteins, tumor necrosis factor alpha and monocyte chemoattractant protein-1, while increased adiponectin serum levels. Rimonabant showed to be more effective than simvastatin. Moreover, concomitant administration of rimonabant and simvastatin achieved the highest effect which nearly normalized most of the studied parameters as compared to singular therapy.
Conclusion:
Rimonabant is the drug of primary choice as singular therapy for obesity. The adjunct therapy of rimonabant with simvastatin may be a novel and a promising therapeutic approach as it has a beneficial effect on the pathophysiological processes of obesity and its associated metabolic disorders.
Insights
Rimonabant and simvastatin effectively treat obesity-related metabolic disorders in rats. Combination therapy showed the most significant improvements, suggesting a promising approach for managing metabolic syndrome.
Area of Science:
- Pharmacology
- Metabolic Disorders
- Obesity Research
Background:
- Obesity is a global health crisis, intricately linked to metabolic syndrome and progressive pathologies.
- Metabolic syndrome encompasses a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.
Purpose of the Study:
- To investigate the therapeutic effects of rimonabant and simvastatin, individually and in combination, on metabolic disorder mediators in diet-induced obese rats.
- To evaluate the impact of these drugs on key indicators of metabolic health and inflammation.
Main Methods:
- Fifty male Wistar rats were divided into five groups: control, high-fat diet (HFD) control, and three HFD groups treated with rimonabant, simvastatin, or a combination for ten weeks.
- Body mass index, lipid profiles, inflammatory markers (TNF-α, MCP-1), and adiponectin levels were assessed.
Main Results:
- Both rimonabant and simvastatin significantly reduced body mass index, total cholesterol, triacylglycerides, LDL, TNF-α, and MCP-1, while increasing adiponectin.
- Rimonabant demonstrated greater efficacy than simvastatin as a monotherapy.
- The combination of rimonabant and simvastatin yielded the most substantial improvements, nearly normalizing most measured parameters.
Conclusions:
- Rimonabant is a primary choice for monotherapy in managing obesity-related metabolic dysfunction.
- Adjunct therapy with rimonabant and simvastatin presents a novel and promising strategy for addressing the pathophysiological processes of obesity and its associated metabolic disorders.
